TrialHeadache2020
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Gary Berman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this paperpooled ittrialcites it